{
    "pmid": "41474050",
    "title": "Discovery of ",
    "abstract": "The dual degradation of cyclin-dependent kinases 12 and 13 (CDK12/13) is a promising therapeutic strategy for triple-negative breast cancer (TNBC), yet identifying clinical candidates with optimized pharmacological profiles remains an ongoing priority. Herein, we describe a rational, structure-based campaign to develop a highly potent and selective degrader. Systematic modification of an initial lead, which showed undesired off-target activity, led to the discovery of ",
    "disease": "breast cancer",
    "clean_text": "discovery of the dual degradation of cyclin dependent kinases and cdk is a promising therapeutic strategy for triple negative breast cancer tnbc yet identifying clinical candidates with optimized pharmacological profiles remains an ongoing priority herein we describe a rational structure based campaign to develop a highly potent and selective degrader systematic modification of an initial lead which showed undesired off target activity led to the discovery of"
}